Please login to the form below

tacrolimus

This page shows the latest tacrolimus news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Teva's generic version of Astellas' Advagraf

The Israeli generics manufacturer’s macrolide immunosuppressant medicinal Tacforius (tacrolimus) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) after demonstrating a “satisfactory quality”

Latest news

AbbVie and J&J file first non-cancer use for Imbruvica with FDA

high-dose steroids on top of immunosuppressants like tacrolimus and cyclosporine.
Astellas sells dermatology unit to Leo for €675m

Skincare specialist Leo is paying 675m for the product portfolio, which is headed by severe eczema treatment Protopic (tacrolimus), Locoid and Locobase skin creams and acne therapy Zineryt (erythromycin/zinc acetate).
Advagraf shows survival increase for liver transplant patients

The study, which comes from the European Liver Transplant Registry (ELTR), found that early use of Advagraf (tacrolimus extended release capsules), a new once-daily formulation of Astellas' immunosuppressant, offers a ... Whilst we do not know the
CHMP backs European approval for six new medicines

Envarsus (tacrolimus), its once-daily drug for the prophylaxis and treatment of organ rejection in adult transplant patients.
Research units to close as Astellas restructures

For fiscal 2012, revenues grew a little under 4 per cent to 1, 000bn yen - driven by immunosupressant Prograf (tacrolimus), Vesicare (solifenacin succinate) for overactive bladder and recently-launched prostate cancer

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest Intelligence

Astellas: Ten years young

diff. Alongside these launches the company has been moving into the oncology arena, adding to its legacy interest in urology from Yamanouchi and Fujisawa, and transplantation, where it has Prograf (tacrolimus)
Deal Watch November 2015

The deal includes Protopic (tacrolimus) for severe eczema treatment, skin creams Locoid and Locobase and acne therapy Zineryt (erythromycin/zinc acetate).
Pharma deals during October 2012

that is in phase III. LCP-Tacro is a novel formulation of tacrolimus based on Veloxis' MeltDose technology, which enhances the bioavailability of compounds with low water solubility. ... 58. †Veloxis Pharmaceuticals / Chiesi Farmaceutici. Licence.
Interview: Ken Jones, Astellas Pharma Europe

In transplantation, three years ago we launched Advagraf, a prolonged-release tacrolimus formulation, which offers the consistency of exposure so vital for transplant recipients.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Account Manager (PR): Great Benefits

Senior External Communications Lead: £Competitive Salary

Experienced medical editor: Competitive salary and bonus scheme

Account Director, Healthcare Communications: Salary TBC

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Publications director: Competitive salary and bonus scheme

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director, Medical Education: Salary TBC

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Digital Associate Director - Medcomms: £65000 - £80000 per annum

Account director: Competitive salary and bonus scheme

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Director: £Competitive Salary

Account Manager: £Competitive Salary

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Subscribe to our email news alerts

PMHub

Add my company

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The ALS patient journey: Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape: Dr Tyler Ray, OPEN Health Medical Communications...
Can protein degraders unlock ‘undruggable’ drug targets?: Exploring a new and exciting area of small-molecule drug discovery...